Clinical trial
Monoclonal Antibody Therapy in Relapsed Non-Hodgkin's After Chemotherapy and…
NCT00031642 · University of Nebraska, Other · Completed
Key facts
| NCT number | NCT00031642 |
|---|---|
| Title | Monoclonal Antibody Therapy in Relapsed Non-Hodgkin's After Chemotherapy and Autologous Stem Cell Transplantation |
| Official title | Phase I/II Study of IDEC-Y2B8 (Zevalin) for Post Transplant Relapses of B-Cell Non-Hodgkin's Lymphoma |
| Lead sponsor | University of Nebraska, Other |
| Collaborators | Biogen Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Lymphoma |
| Intervention type | Biological, Radiation |
| Interventions | rituximab, yttrium Y 90 ibritumomab tiuxetan |
| Enrollment | 26 |
| Start date | Jan 1, 2002 |
| Primary completion | Nov 1, 2005 |
| Completion | Mar 1, 2008 |
| First posted | Jan 27, 2003 |
| Last update posted | Dec 27, 2023 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: